Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma

Blood

Volumn 95, Issue 2, 2000, Pages 619-626

  Chiarle, Roberta ^a   Budel, Leo M ^b   Skolnik, Jeffrey ^a   Frizzera, Glauco ^b   Chilosi, Marco ^c   Corato, Alessandra ^d   Pizzolo, Gianni ^b   Magidson, Jory ^c   Montagnoli, Aiessia ^d   Pagano, Michèle ^e   Maes, Brigitte ^a   De Wolf Peelers, Christine ^b   Inghirami, Giorgio ^a,e,f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY OF VERONA   (Italy)

^d MORRISTOWN MEMORIAL HOSPITAL   (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEASOME; PROTEIN P27;

ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; GENE CONTROL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

EID: 12944283204     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.2.619     Document Type: Article

References (69)

1. Nakamura S, Yatabe Y, Kuroda H, et al. Immunostaining of PRAD1/cyclin D1 protein as a marker for the diagnosis of mantle cell lymphoma. Leukemia. 1997;11(suppl 3):536-537.
2. de Boer CJ, van Krieken JH, Schuuring E, Kluin PM. Bcl-1/cyclin D1 in malignant lymphoma. Ann Oncol. 1997;8(suppl2):109-117.
3. Yatabe Y, Nakamura S, Seto M, et al. Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma: a distinct molecular pathologic entity. Am J Surg Pathol. 1996;20:11 ID1122.
4. Loyson SA, de Boer CJ, Schuuring E, Kluin PM, van Krieken JH. Mantle ceil lymphoma: a morphological, immunohistochemical and molecular genetic study. Pathol Res Pract. 1996;192:781-789.
5. Raffeld M, Jaffe ES. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood. 1991;78:259263.
6. De Wolf-Peeters C, Pittaluga S. Mantle-cell lymphoma. Ann Oncol. 1994;5(suppl 1):35-37.
7. Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin DI gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 1994:84:27262732.
8. de Boer CJ, Schuuring E, Dreef E, et al. Cyclin DI protein analysis in the diagnosis of mantle cell lymphoma. Blood. 1995:86:2715-2723.
9. Ott MM, Helbing A, Ott G, et al. bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma. J Pathol. 1996:179:238-242.
10. Kumar S, Krenacs L, Otsuki T, et al. bcl-1 rearrangement and cyclin D1 protein expression in multiple lymphomatous polyposis. Am J Clin Pathol. 1996:105:737-743.
11. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of nonHodgkin's lymphoma. Blood. 1997:89:3909-3918.
12. Lardelli P, Bookman MA, Sundeen J, Longo DL, Jaffe ES. Lymphocytic lymphoma of intermediate differentiation: morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol. 1990:14:752-763.
13. Duggan MJ, Weisenburger DD, Ye YL, et al. Mantle zone lymphoma: a clinicopathologic study of 22 cases. Cancer. 1990:66:522-529.
14. Fisher Rl, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lym" phoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995:85:10751082.
15. Fisher Rl. Mantle-cell lymphoma: classification and therapeutic implications. Ann Oncol. 1996;7 (suppl 6):S35-S39.
16. Swerdlow SH, Zukerberg LR, Yang Wl, Harris NL, Williams ME. The morphologic spectrum of nonHodgkin's lymphomas with BCLI/cyclin D1 gene rearrangements. Am J Surg Pathol. 1996:20:627-640.
17. Weisenburger DD, Armitage JO. Mantle cell lymphoma: an entity comes of age. Blood. 1996;87: 4483-4494.
18. Zoldan MC, Inghirami G, Masuda Y, et al. Largecell variants of mantle cell lymphoma: cytologie characteristics and p53 anomalies may predict poor outcome. Br J Haematol. 1996:93:475-486.
19. Soslow RA. Zukerberg LR, Harris ML, Warnke RA. BCL-1 (PRAD-1/cyclin D-1) overexpression distinguishes the blastoid variant of mantle cell lymphoma from B-lineage lymphoblastic lymphoma. Mod Pathol. 1997;10:810-817.
20. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
21. Ott MM, Ott G, Kuse R, et al. The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl-1 gene and high proliferation indices. Histopathology. 1994:24: 329-334.
22. Ott G, Kalla J, Ott MM, et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood. 1997; 89:1421-1429.
23. Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1995:87:4302-4310.
24. Hernandez L, Fest T, Cazorla M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood. 1996:87:3351-3359.
25. Louie DC, Offit K, Jaslow R, et al. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood. 1995:86:2892-2899.
26. Williams ME, Whitefield M, Swerdlow SH. Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. Ann Oncol. 1997;8 (suppl 2):71-73.
27. Pinyol M, Hernandez L, Cazorla M, et al. Deletions and loss of expression of p16lNK4a and p21 Wad genes are associated with aggressive variants of mantle cell lymphomas. Blood. 1997; 89:272-280.
28. Hunter T, Pines J. Cyclins and cancer, II: cyclin D and CDK inhibitors come of age. Cell. 1994;79: 573-582.
29. Yamasaki L. Growth regulation by the E2F and DP transcription factor families. Results Probl Cell Differ. 1998:22:199-227.
30. Nevins JR, DeGregori J, Jakoi L, Leone G. Functional analysis of E2F transcription factor. Methods Enzymol. 1997;283:205-219.
31. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993:75:817-825.
32. Dulic V, Kaufmann WK, Wilson SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 1994:76:1013-1023.
33. Sherr CJ, Roberts JM, Inhibitors of mammalian
34. G1 cyclin-dependent kinases. Genes Dev. 1995; 9:1149-1163.
35. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998;159: 941-945.
36. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997; 57:3381-3385.
37. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclindependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231-234.
38. Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1 a,b) invasive breast carcinomas. Cancer Res. 1997;57:1259-1263.
39. Pittaluga S, Tierens A, Pinyol M, Campo E, Delabie J, De Wolf-Peelers C. Elastic van'ant of mantle cell lymphoma shows a heterogenous pattern of somatic mutations of the rearranged immunoglobulin heavy chain variable genes. Br J Haematol. 1998:102:1301-1306.
40. Pittaluga S, Wlodarska !, Stul MS, et al. Mantle cell lymphoma: a clinicopathological study of 55 cases. Histopathology. 1995;26:17-24.
41. Helin K, Hartow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol. 1993;13:6501 -6508.
42. Helin K, Wu CL, Fattaey AR, et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev. 1993;7:1850-1861.
43. Chilosi M, Doglioni C, Menestrina f, et al. Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood. 1994;84:4295-4300.
44. Yee HT, Ponzoni M, Merson A, et al. Molecular characterization of the t(2;5) (p23;q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease. Blood. 1996:87:1081-1088.
45. Pagano M, Draetta G, Jansen-Durr P. Association of cdk2 kinase with the transcription factor E2F during S phase. Science. 1992:255:1144-1147.
46. Meyer EM, West CM, Chau V. Antibodies directed against ubiquitin inhibit high affinity [3H]choline uptake in rat cerebral cortical synaptosomes. J BiolChem. 1986,'261:14,365-14,368.
47. Gussow D, Rein R, Ginjaar I, et al. The human beta 2-microglobulin gene: primary structure and definition of the transcriptional unit. J Immunol. 1987:139:3132-3138.
48. Pagano M, Tam SW, Theodoras AM. et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995:269:682-685.
49. Haas AL, Rose IA. Hemin inhibits ATP-dependent ubiquitin-dependent proteolysis: role of hemin in regulating ubiquitin conjugate degradation. Proc Natl Acad Sei USA. 1981;78:6845-6848.
50. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haploinsufiicient for tumour suppression. Nature. 1998; 396:177-180.
51. Quintanilla-Martinez L, Thieblemont C, Fend F, et al. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol. 1998:153:175-182.
52. Reld SJ, Tsai FY. Kuo F, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 1996:85:549-561.
53. 52.' " Yamasaki L, Jacks T, Bronson R, Goulot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell. 1996:85:537548.
54. Lai R, Medeiros LJ, Coupland R, McCourty A, Brynes RK. Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases. Mod Pathol. 1998:11:457-463.
55. Lai R, Medeiros LJ, Wilson CS, et al. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity. Mod Pathol. 1998:11:642-647.
56. Cordon-Cardo C, Koff A, Drobnjak M, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatio carcinoma. J Natl Cancer Inst. 1998:90:1284-1291.
57. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science. 1996:271:1861-1864.
58. Millard SS, Van JS, Nguyen H, Pagano M, Kiyokawa H, Koff A. Enhanced ribosomal association of p27(Kip1) mRNAis a mechanism contributing to accumulation during growth arrest. J Biol Chem. 1997:272:7093-7098.
59. Morosetti R, Kawamata N, Gombart AF, et al. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/Iymphoma. Blood. 1995:86:1924-1930.
60. Spinn KS. Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP. p27/Kip1 mutation found in breast cancer. Cancer Res. 1996:56:24002404.
61. Stegmaier K, Pendse S, Barker GF, et al. Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood. Blood. 1995:86:38-44.
62. Stegmaier K, Takeuchi S, Golub TR, Bohlander SK, Bartram CR, Koeffler HP. Mutational analysis of the candidate tumor suppressor genes TEL
63. and KIP1 in childhood acute lymphoblastic leukemia. Cancer Res. 1996:56:1413-1417.
64. Pietenpol JA, Bohlander SK, Sato Y, et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 1995;55: 1206-1210.
65. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996:85:707-720.
66. Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1).Cell. 1996:85:721-732.
67. Fero ML, Rivkin M, Tasch M, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)deficient mice. Cell. 1996:85:733-744.
68. Park MS, Rosai J, Nguyen HT, Capodieci P,
69. Cordon-Cardo C, Kofl A. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Nail Acad Sei U S A. 1999:96:63826387.